Cargando…
Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma
BACKGROUND: Patients with severe asthma often require oral corticosteroid (OCS) treatment. Clinical trials have demonstrated that mepolizumab can reduce OCS dependence, but real-world data are limited. OBJECTIVE: To evaluate the impact of mepolizumab on OCS use, asthma exacerbations, and asthma exac...
Autores principales: | Silver, Jared, Bogart, Michael, Packnett, Elizabeth, Wu, Juan, McMorrow, Donna, Hahn, Beth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751313/ https://www.ncbi.nlm.nih.gov/pubmed/33364788 http://dx.doi.org/10.2147/JAA.S275944 |
Ejemplares similares
-
Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States
por: Silver, Jared, et al.
Publicado: (2023) -
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
por: Llanos, Jean-Pierre, et al.
Publicado: (2020) -
Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI
por: Bogart, Michael, et al.
Publicado: (2023) -
Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies
por: Casale, Thomas B., et al.
Publicado: (2022) -
Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
por: Llanos, Jean-Pierre, et al.
Publicado: (2019)